EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents

Mei-Juan Lan, Di-Fei Yao, Ling-Ling Zhu, Quan Zhou iD

Risk Management and Healthcare Policy · 2023-11 · Volume 16 · 2531-2541

DOI: 10.2147/rmhp.s442692 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Risk Management and Healthcare Policy, 2023-11. Verfasst von Mei-Juan Lan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nursing, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infusion rate is one of the essential elements that should be included in all intravenous orders. Patients may experience adverse consequences or risks associated with inappropriate infusion. Meanwhile, there is growing pressure on the chemotherapy unit to deliver treatment quickly, efficiently, and safely, and thus it is very necessary to improve the chemotherapy process and service to cancer patients. Clinicians should consider how to further standardize infusion therapy, and innovate new infusion strategies to increase efficacy, reduce toxicity, improve patient satisfaction and save health resource costs. Sporadic studies have evaluated the effects of infusion rates of anticancer agents on clinical outcomes, economic benefits, and administration efficiency. However, an update review has not been available.

Methods

Relevant literature was identified by search of PubMed until September 2023.

Results

Infusion rates may have significant effect on the efficacy of anticancer agents (e.g., methotrexate, fluorouracil, and arsenic trioxide). Slow infusion is safer for platinum compounds, doxorubicin and carmustine, whereas fast infusion is safer than slow infusion of gemcitabine. Optimal flow rates of paclitaxel and fluorouracil are based on the balance between multiple risks of toxicity. Optimal infusion rate may bring economic benefits. If efficacy and safety are not compromised, shortened infusion may result in higher patient satisfaction, improved institutional efficiency and more nursing time available for other activities (e.g., biosimilar products, endostar). Other concerns about infusion rate include clinical indications (eg, paclitaxel and rituximab, methotrexate), severity and type of hypersensitivity reactions (e.g., platinum compounds), formulation features (e.g., paclitaxel, doxorubicin), and genetic polymorphism (e.g., gemcitabine, methotrexate).

Conclusion

The latest knowledge of infusion rate concerns will enhance the appropriateness and accuracy in intravenous administration. Interdisciplinary teams should collaborate and implement relevant risk management and healthcare policy. It is worthwhile to conduct comparative studies of intravenous therapy with different infusion speeds.

Schlagwörter

Stichwörter der Autor:innen

anticancer agentsefficacyhealthcare policyinfusion ratemedication administrationpharmacoeconomicssafety

Autor:innen und Institutionen

  • Division of Nursing, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
  • Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
  • Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Changxing Campus of the Second Affiliated Hospital of Zhejiang University, Huzhou, Zhejiang Province, People's Republic of China.
  • VIP Geriatric Ward, Division of Nursing, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.

ORCID-Profile: Quan Zhou

Zitieren

APA

Lan, M. J., Yao, D. F., Zhu, L. L., & Zhou, Q. (2023). The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents. Risk Management and Healthcare Policy, Volume 16, 2531-2541. https://doi.org/10.2147/rmhp.s442692

Vancouver

Lan MJ, Yao DF, Zhu LL, Zhou Q. The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents. Risk Management and Healthcare Policy. 2023;Volume 16:2531-2541. doi:10.2147/rmhp.s442692

BibTeX
@article{Lan2023,
  author = {Lan, Mei-Juan and Yao, Di-Fei and Zhu, Ling-Ling and Zhou, Quan},
  title = {The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents},
  journal = {Risk Management and Healthcare Policy},
  year = {2023},
  volume = {Volume 16},
  pages = {2531--2541},
  doi = {10.2147/rmhp.s442692}
}
Kostenlos starten →